![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
Listed Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
https://www.businesswire.com/news/home/20220920005346/en/Puma-Biotechnology-Announces-Exclusive-License-Agreement-with-Takeda-for-the-Development-and-Commercialization-of-Alisertib-an-Investigational-Aurora-Kinase-A-Inhibitor
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216236
https://www.prnewswire.com/news-releases/nccn-oncology-research-program-and-puma-biotechnology-inc-collaborate-to-study-neratinib-in-various-cancers-301152638.html
https://www.globenewswire.com/news-release/2020/09/03/2088839/0/en/Knight-Therapeutics-Announces-Filling-of-Supplement-to-a-New-Drug-Submission-for-NERLYNX-neratinib-to-Treat-HER2-Positive-Metastatic-Breast-Cancer.html
https://www.biospectrumasia.com/news/25/16475/taiwan-approves-new-drug-for-early-breast-cancer-treatment.html
https://www.businesswire.com/news/home/20200806006073/en/CANbridge-Pharmaceuticals-Receives-Marketing-Approval-NERLYNX%C2%AE-neratinib#:~:text=BEIJING%20%26%20SHANGHAI%2D%2D(BUSINESS%20WIRE,%C2%AE%20(neratinib)%20for%20the%20extended
https://www.businesswire.com/news/home/20200721005266/en/Acentrus-Specialty-Partners-Puma-Biotechnology-Bring-Nerlynx%C2%AE
https://www.biospectrumasia.com/news/25/16317/malaysia-approves-new-early-breast-cancer-drug.html
https://en.prnasia.com/releases/global/new-early-breast-cancer-drug-now-approved-in-malaysia-285622.shtml
https://www.businesswire.com/news/home/20200716005844/en/Puma-Biotechnology-Licensing-Partner-Specialised-Therapeutics-Receives
https://www.biospectrumasia.com/news/25/16317/malaysiaa-npra-approves-new-early-breast-cancer-drug.html
https://www.biospectrumasia.com/news/26/15887/bixink-to-bring-new-breast-cancer-drug-to-korea.html
https://www.biospectrumasia.com/news/51/15887/bixink-to-bring-new-breast-cancer-drug-to-korea.html
https://www.prnewswire.com/news-releases/new-early-breast-cancer-drug-available-now-in-singapore-301045859.html
https://www.prnewswire.com/news-releases/new-early-breast-cancer-drug-available-now-in-singapore-301045859.html
https://www.targetedonc.com/news/fda-approves-supplemental-nda-for-neratinib-in-metastatic-her2positive-breast-cancer
https://www.fiercebiotech.com/medtech/db-babson-pair-up-to-bring-capillary-blood-draws-to-retail-pharmacies
https://www.businesswire.com/news/home/20191211005896/en/Puma-Biotechnology-Presents-Results-Phase-II-SUMMIT/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==
https://www.biospectrumasia.com/news/25/15014/singapore-approves-new-early-breast-cancer-drug.html
https://www.businesswire.com/news/home/20191202005211/en/Puma-Biotechnology-Amends-License-Agreement-Pierre-Fabre
https://www.businesswire.com/news/home/20190903005879/en/FDA-Grants-Orphan-Drug-Designation-Puma-Biotechnology%E2%80%99s
http://www.pharmafile.com/news/525880/nice-recommends-pierre-fabres-nerlynx-adjuvant-her2-breast-cancer
https://www.evaluate.com/vantage/articles/news/snippets/disappointing-nerlynx-sales-shows-pierre-fabre-timing-everything
https://www.fiercepharma.com/marketing/puma-biotech-s-nerlynx-suffers-a-terrible-quarter-what-gives
https://www.raps.org/news-and-articles/news-articles/2019/1/ema-sees-spike-in-medicines-recommendations-in-201?utm_source=MagnetMail&utm_medium=Email%20&utm_campaign=RF%20Today%20%7C%204%20January
https://www.businesswire.com/news/home/20181217005783/en/Puma-Biotechnology-Announces-Top-Line-Results-Phase/
https://www.businesswire.com/news/home/20181002005126/en/CANbridge-Pharmaceutical-Submits-New-Drug-Application-NERLYNX%C2%AE/
https://www.ema.europa.eu/documents/product-information/nerlynx-epar-product-information_en.pdf
https://www.biocentury.com/bc-extra/company-news/2018-09-04/ec-approves-pumas-nerlynx-adjuvant-breast-cancer
https://endpts.com/chmp-reverses-course-on-neratinib-handing-puma-an-unexpected-win-on-european-marketing-vote/
https://www.raps.org/news-and-articles/news-articles/2018/3/ema%E2%80%99s-chmp-rejects-two-drugs-approved-by-us-fda-in
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/03/news_detail_002925.jsp&mid=WC0b01ac058004d5c1